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Tumors of the urethra, whether primary or metastatic, are very rare. The true nature of urethral
neoplasm is not always obvious clinically nor in routine histological sections. Immunostains should be
performed on such lesions because of management implications. We present a case of multiple me-
tastases to the urethra from a prostatic carcinoma, masquerading as multiple urothelial carcinomas.
Pathologists and urologists should be aware of the possibility of metastasis from the prostate.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Tumors of the urethra, whether primary or metastatic, are very
rare.1 We present a case of multiple metastases to the urethra from
a prostatic carcinoma, masquerading as multiple urothelial
carcinomas.
An 84 year old man presented in January 2014 with urinary
retention and symptoms of urinary tract infection. Cystoscopy
(Fig. 1, panels A, B and C) revealed 3 polypoid urethral lesions. One
of the lesions was in themembranous urethra and the other 2 in the
spongy (bulbar and penile) urethra. The bladder was normal. Cold
cup biopsies of the urethral lesions and transurethral resection of
the prostate (TURP) were performed.
All the urethral biopsies showed high grade malignant
papillary neoplasms with exophytic growth patterns (Fig. 2,
panels A to D). The tumors in the spongy/distal parts of the
urethra were non-invasive but the tumor in the membranous
urethra had invaded muscle (Fig. 2, panel A). The prostatic tissue
was benign except for loose fragments of papillary neoplasm,
similar to the urethral tumors. The urethral cancers were
initially regarded as high grade urothelial carcinomas but in
view of the unusual presentation of multiple urethral tumor inathology, 6 Sydney Street,
u.au, izardawi@dhm.com.au
Inc. This is an open access article uthe absence of bladder involvement at cystoscopy, immunos-
tains were performed. These showed strong PSA positivity
(Fig. 2, panel E). Alpha-Methylacyl-CoA racemase (AMACR) was
also positive (Fig. 2, panel F). Special stains for mucin were
negative. Retrospective evaluation of the routine Hematoxylin
and Eosin stained sections showed the tumor to be made up of
tall pseudostratiﬁed cells with some glandular arrangements
(Fig. 2, panel D).
Review of the past medical history indicated an indolent
prostate cancer diagnosed in 2004 on digital rectal examination
and by raised serum prostate speciﬁc antigen (PSA) level of
10.3 ug/L (age adjusted reference interval is <6.5 ug/L). He had
been managed with active surveillance and his PSA levels between
2004 and 2014 had ﬂuctuated between 9 ug/L and 11 ug/L. TURP,
performed in 2011 for urinary retention, yielded benign prostate
tissue only. He presented in September 2014, with metastatic
cancer in his right lung. The tumor, a poorly differentiated pros-
tatic adenocarcinoma, strongly expressed PSA (Fig. 3, panel B),
prostein/p501s (Fig. 3, panel C) and CD10 (Fig. 3, panel D). He is
currently clinically stable on androgen deprivation therapy with a
PSA level of 15 ug/L.
Primary penile urethral carcinoma is a very rare male genital
tract cancer. Metastatic tumors are even less frequent. These
usually originate in the bladder, prostate or the gastrointestinal
system.1 In a recent review of 29 cases of metastatic prostate
cancers to the penis, Ellis and Epstein found 16 (55.2%) of themnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Cystoscopic images of the urethra. Panel A shows an exophytic growth in the penile part of the spongy urethra. Panel B is the tumor in the bulbar part of the spongy
urethra. Panel C displays the lesion in the membranous urethra near the verumontanum. Panel D depicts the open prostatic urethra after the TURP.
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the remainder had their origin in usual acinar adenocarcinomas.2
The tumor in our case has features of a high grade prostatic
acinar carcinoma.
Metastases from prostate carcinoma to the urethra show a
number of architectural patterns, including papillary, cribriform,
single glands, features reminiscent of high grade prostatic intra-
epithelial neoplasia (PIN) and Pagetoid morphology.2,3 Because
the tumors, in our case, had a prominent papillary growth
pattern, they were initially considered as primary urethral can-
cers of urothelial origin. Primary urothelial cancers of the urethra
often accompany urothelial cancers in the bladder or other parts
of urinary system. Finding multiple cancers in the urethra
without bladder involvement made us consider other possibil-
ities and perform immunostains. The true nature of the tumor
only became apparent after immunostains. This is a recognized
pitfall, acknowledged by Ellis and Epstein and Tu and colleagues.
In the series by Ellis and Epstein, 3 of the 29 cases were initially
diagnosed as urothelial carcinomas. This experience was also
shared by Tu and colleagues who misinterpreted one of their
cases of penile metastatic tumor from the prostate as a primary
urethral cancer.4
Urothelial and some prostatic carcinomas appear to overlap
morphologically and some of the poorly differentiated prostatic
carcinomas can be negative for PSA by immunohistochemistry.
Even serum PSA may not be elevated.5 Other immunostains to
prove prostatic origin and exclude urothelial cancer should be
employed as no unequivocal deﬁning morphological to distinguishprostatic ductal carcinoma from high grade urothelial carcinoma
exist.
The route of spread to the urethra is unclear and no single
mechanism can explain it adequately because the urethra is a
complex structure and its 4 parts lie in different anatomical
compartments. The spongy anterior urethra with its bulbar and
penile parts is situated in the navicular fossa which lies below the
pelvic ﬂoor. The membranous (rhabdosphincter) part of the ure-
thra lies within the pelvic ﬂoor in the perineal region. The pos-
terior (prostatic/bladder neck) part of the urethra which is located
above the pelvic ﬂoor descends through the anterior part of the
prostate. The pre-prostatic urethrawhich also lies above the pelvic
ﬂoor extends vertically from bladder neck to the posterior aspect
of the prostate and is associated with the internal urethral
sphincter. Direct involvement, seeding and retrograde venous or
lymphatic spread have been suggested as possibilities.2 In our
patient, the biopsies from the anterior (distal) urethra showed
surface involvement only, whereas the sample from the mem-
branous (middle) urethra also showed invasive carcinoma. The
proximal urethra was uninvolved clinically. The TURP were his-
tologically uninvolved.
In general, patients with metastatic prostate cancer to the ure-
thra have a poor prognosis because they are usually seen in
advanced stages of prostate cancer. Approximately 50% of patients
with follow-up information are dead within 2 years following the
penile metastasis.6 A case report and review of the literature by
Kotake and colleagues of 25 cases from 3 publications of prostate
carcinoma, appears to conﬁrm the above observations.7
Figure 2. The main histological and immunehistochemical features of the tumors in the penile urethra are illustrated. Panel A shows an invasive neoplasm with a papillary surface
growth pattern and extension into the underlying urethral wall muscle. A clear papillary architecture is seen Panels A to D. Pseudostratiﬁed columnar cells and gland like spaces are
seen in Panel D. PSA and AMACR positivity are seen in the tumor cells in Panels E and F respectively. The urothelium overlying the invasive tumor is high molecular weight
cytokeratin 34bE12 positive (Panel F). Occasional PSA positive (brown) cells, indicative of focal surface involvement by prostatic carcinoma are noted on the surface (Panel E).
AMACR (red) is positive in the invasive tumor cells and also within some of the surface urothelium (Panel F). Panel F is a dual stain for AMACR detected with red chromogen (Fast
Red) and 34bE12 detected with brown chromogen (Diaminobenzidine).
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prostate in the absence of bony metastases. Hematogenous
spread to the spine, believed to take place via a backward
metastatic pathway, is the most common method of distant
metastasis in prostate cancer. Bony metastases usually precede
spread via the vena cava and there is an inverse relationship
between spine and lung metastases. Furthermore spine
involvement is more frequent with smaller prostatic tumors
when compared to those that metastasize to lung or liver.8 Ourpatient does not have bony metastases and his primary tumor is
relatively small. However, his lung metastases also express
CD10, which has been shown to represent a marker for a more
aggressive phenotype with a higher malignant and possibly
metastatic potential.9
The true nature of urethral neoplasm is not always obvious in
routine sections. Immunostains should be performed on such
lesions because of management implications. Pathologists should
be aware of the possibility of metastasis from the prostate.
Figure 3. The main morphological and immunohistochemical characteristics of the lung metastasis are shown. The tumor (Panel A) is a poorly differentiated adenocarcinoma with
tall columnar cells displaying some pseudostratiﬁcation. The tumor cells expresse PSA (Panel B), Prostein/p501s (Panel C) and CD10 (Panel D). Immunoreactivity is detected by the
chromogen Diaminobenzidine (brown).
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